1. ALLA AKTIER
  2. NYHETER
  3. ALLIGATOR BIOSCIENCE

Alligator Bioscience

Nyheter Alligator Bioscience Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Alligator Bioscience publishes Annual Report for 2022

REG

Lund, Sweden, March 24, 2023 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2022 has been published. Because of environmental and cost reasons, Alligator Bioscience has chosen not to print the annual report.

The Annual Report is attached as a PDF and is available on the company’s website.

For further information, please contact:

Søren Bregenholt, CEO
E-mail: soren.bregenholt@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00

Marie Svensson, CFO
E-mail: marie.svensson@alligatorbioscience.com
Phone: +46 (0) 46 540 82 03

This information is information that Alligator Bioscience is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-03-24 11:00 CET.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

Alligator Annual Report 2022 EN VF
549300E15VI0MB7LXV19 2022 12 31 Sv
549300E15VI0MB7LXV19 2022 12 31 Sv

Datum 2023-03-24, kl 11:00
Källa MFN
Bifogade filer
Alligator Annual Report 2022 EN VF
549300E15VI0MB7LXV19 2022 12 31 Sv
549300E15VI0MB7LXV19 2022 12 31 Sv